Sclerostin inhibitors enhance bone health and reduce fracture risk but may increase cardiovascular risk. Here, authors show that lower sclerostin levels are associated with a higher risk of coronary artery disease, type 2 diabetes, and adverse cardiovascular biomarkers across the lifespan.
- Marta Alcalde-Herraiz
- JunQing Xie
- Albert Prats-Uribe
